LIVE :
1.6 EUR
FR
EN
≡
About
Company
Allergy
Medical Need
Therapeutic strategies & Market
Platform
ASIT+™ Platform
TM
Production process
Mode of action
Leadership
Management
Board of Directors
Scientific Advisory Board
Partners Welcome
Pipeline
Pipeline
gp-ASIT+
TM
hdm-ASIT+
TM
pnt-ASIT+
TM
Other programs
Scientific Publications
Investors
Share information
Share price
Shareholder structure
Analysts Coverage
Shareholders meetings
EGM of November 14, 2019
EGM of June 28, 2019
OGM of June 13, 2019
EGM of December 17, 2018
OGM of June 14, 2018
EGM of December 7, 2017
EGM of June 8, 2017
OGM of June 8, 2017
AGM of June 30, 2016
Financial Information
Financial Calendar & Events
Annual Reports
Corporate Information
Corporate presentations
Corporate Governance
Audit Committee
Compensation and Nomination Committee
FSMA Regulated Information
Scientific Publications
Press releases & media
Press releases
Videos
Career
Spontaneous Applications
Contact
ASIT biotech takes important steps in US clinical development of gp-ASIT+™, its lead drug candidate for grass pollen rhinitis
PR_FDA_vf_EN.pdf
14 November 2016
ASIT biotech takes important steps in US clinical development of gp-ASIT+™, its lead drug candidate for grass pollen rhinitis
Download the press release
PDF
